Esperion Therapeutics Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
26.8 M |
Public Float |
24.26 M |
Esperion Therapeutics Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$2.74 |
Market Cap |
$1.27 B |
Shares Outstanding |
26.92 M |
Public Float |
24.9 M |
Address |
3891 Ranchero Drive Ann Arbor Michigan 48108 United States |
Employees | - |
Website | http://www.esperion.com |
Updated | 07/08/2019 |
Esperion Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). It offers Bempedoic acid and Ezetime combination pill as therapies that have been shown to lower elevated LDL-C levels in patients with hypercholesterolemia, including patients inadequately treated with current lipid-modifying therapies. The company was founded by Roger S. |